Search

Your selection

Clear all

Filter by content type

Filter by content year

News

Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update

November 12, 2019 - …   —     Intangible assets, net     17,526       19,413     Total Assets   $ 42,695     $ 35,227                       …     Operating lease liabilities     2,514       —     Total liabilities     23,792       23,989     Stockholders’ equity     18,903       11,238     Total liabilities and stockholders’ equity   $ 42,695     $ …
News

Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study

September 25, 2019 - … The Phase 1b norovirus bivalent vaccine trial enrolled a total of 80 subjects. After enrollment of an open-label … The Phase 1b norovirus bivalent vaccine trial enrolled a total of 80 subjects. After enrollment of an open-label … The Phase 1b norovirus bivalent vaccine trial enrolled a total of 80 subjects. After enrollment of an open-label …
News

Vaxart Announces Second Quarter 2019 Financial Results and Provides Corporate Update

August 8, 2019 - … 565       — Intangible assets, net     17,959       19,413 Total Assets   $ 37,250     $ 35,227                 …       3,611 Operating lease liabilities     781       — Total liabilities     21,405       23,989 Stockholders’ equity     15,845       11,238 Total liabilities and stockholders’ equity   $ 37,250     $ …
News

Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update

May 9, 2019 - … shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million . On … the pricing of an underwritten public offering of a total of 925,455 shares of common stock and 8,165,455 … assets, net 762 — Intangible assets, net   18,634   19,413 Total assets $ 36,309 $ 35,227   Liabilities and …
News

Vaxart Announces Closing of Registered Direct Offering of Common Stock

March 20, 2019 - … shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million , … shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million , … shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million , …
News

Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

March 19, 2019 - … a double-blind, placebo-controlled phase during which a total of 80 subjects will be randomized into four groups and … a double-blind, placebo-controlled phase during which a total of 80 subjects will be randomized into four groups and … a double-blind, placebo-controlled phase during which a total of 80 subjects will be randomized into four groups and …
News

Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

February 6, 2019 - … net 1,066 730 Intangible assets, net   19,413     40   Total assets $ 35,227   $ 4,523     Liabilities and … promissory notes, related party   —     35,282   Total liabilities 23,989 43,245 Stockholders’ equity (deficit)   11,238     (38,722 ) Total liabilities and stockholders’ equity (deficit) $ 35,227 …
Scroll to Top